ArticleInternational journal of clinical and experimental pathology2018
miR-455-3p functions as a tumor suppressor in colorectal cancer and inhibits cell proliferation by targeting TPT1.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- MiR-455-3p inhibits gastric cancer progression by repressing Wnt/β-catenin signaling through binding to ARMC8.BMC medical genomics · 2023Article
- ANP32A Knockdown Attenuates the Malignant Biological Behavior of Colorectal Cancer Cells by Suppressing Epithelial-mesenchymal Transition and ERK Activation.Journal of Cancer · 2023Article
- LINC00472 suppresses oral squamous cell carcinoma growth by targeting miR-455-3p/ELF3 axis.Bioengineered · 2022Article
- Long non-coding RNA DLEU2 drives EMT and glycolysis in endometrial cancer through HK2 by competitively binding with miR-455 and by modulating the EZH2/miR-181a pathway.Journal of experimental & clinical cancer research : CR · 2021Article
- Characterization of the Cellular Microenvironment and Novel Specific Biomarkers in Pterygia Using RNA Sequencing.Frontiers in medicine · 2021Article
- Potential Target miR-455 Delaying Arterial Stenosis Progression Through PTEN.Frontiers in cardiovascular medicine · 2021Article
- MiR-455-3p downregulation facilitates cell proliferation and invasion and predicts poor prognosis of osteosarcoma.Journal of orthopaedic surgery and research · 2020Article
- CircCSNK1G1 Contributes to the Development of Colorectal Cancer by Increasing the Expression of MYO6 via Competitively Targeting miR-455-3p.Cancer management and research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing studies have revealed the importance of microRNAs (miRNAs) in tumorigenesis and tumor progression. miR-455-3p is a newly identified tumor suppressive RNA in various human cancers. However, the expression pattern and clinical significance of miR-455-3p in colorectal cancer (CRC) remains unclear. We found that expression of miR-455-3p was significantly reduced in CRC tissues and cell lines. In addition, we show that low miR-455-3p expression is associated with larger tumor size, advanced tumor stage, and poorer overall survival of CRC patients. Furthermore,
Indexed as
Identifiers
31938365PMC6958251W3013293159What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.